Skip to NavigationSkip to content

Bayer to cut 227 positions in California to drive efficiency in haemophilia

Published on 04/10/18 at 11:32am

Bayer has announced its intention to axe 227 employees at a manufacturing site in California as part of a push to drive greater operational efficiencies in its haemophilia business.

Half of the total layoffs will come into effect immediately. Bayer has said that the cuts will have no effect on access for patients to its treatments. The company be left with around 1,100 staff in total after the planned departures.

The move is thought to come in response to pressure within the haemophilia space, as sales of two of its three recombinant factor VIII therapies were impacted by a planned termination agreement with a distribution partner, dropping 20% to €427 million from the previous year.

“The manufacturing processes for these products must […] be robust and efficient to ensure product safety, reliable supply, and to remain competitive in support of new therapies that position the long term viability of the site,” the company said in a statement. “Our transition into commercial production with three products has resulted in the need for organisational changes to enable these efficiencies, and today we notified 227 employees that their positions were being eliminated as part of this reorganisation.

“We have the utmost appreciation for the employees affected by this reorganisation, and will ensure that we manage their transition in the most respectful and thoughtful manner that we can.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches